10-Q: Pulmatrix Announces Merger with Eos, Secures $19M Financing

Pulmatrix, Inc. reported its Q1 2026 results, detailing a proposed merger with Eos SENOLYTIX, Inc. and concurrent private financings totaling $19 million.

Summary

• Pulmatrix, Inc. has entered into a Merger Agreement with Eos SENOLYTIX, Inc. (Eos) on March 26, 2026, where Pulmatrix's subsidiary will merge with Eos, making Eos a wholly-owned subsidiary of Pulmatrix.
• Concurrent with the merger, private financings totaling $19 million in aggregate gross proceeds have been agreed upon, including a $1.0 million investment in Pulmatrix.
• Post-merger, Eos stockholders are expected to own approximately 94% of the combined company, with Pulmatrix stockholders owning approximately 6% on a fully-diluted basis.
• The company reported a net loss of $1.172 million for the three months ended March 31, 2026, compared to a net loss of $1.808 million for the same period in 2025.
• Cash and cash equivalents stood at $3.324 million as of March 31, 2026, with $0.7 million in restricted cash.
• Research and development expenses decreased significantly to $3 thousand from $19 thousand in the prior year's quarter, reflecting a pause in clinical development.
• General and administrative expenses decreased to $1.289 million from $1.828 million in the prior year's quarter, primarily due to lower costs related to SEC filings.
• The company's future operations are highly dependent on the success of the Merger; if not consummated, the board may pursue dissolution and liquidation.
• Pulmatrix has paused development of its product candidates PUR3100, PUR1800, and PUR1900, and is exploring opportunities to monetize these assets.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the substantial doubt about going concern, continued net losses, and the high dependence on a merger for survival, despite the secured financing and merger agreement.

Positives

• Secured $19 million in aggregate gross proceeds from concurrent private financings.
• Entered into a Merger Agreement with Eos SENOLYTIX, Inc., which, if completed, will combine businesses and potentially provide a path forward.
• Net loss decreased to $1.172 million in Q1 2026 from $1.808 million in Q1 2025.
• General and administrative expenses decreased by approximately $0.5 million due to reduced SEC filing preparation costs.
• PUR3100 Phase 1 study showed favorable safety and tolerability compared to IV DHE, with rapid systemic exposure.
• PUR1800 Phase 1b study indicated safety and tolerability with low systemic exposure, supporting potential chronic dosing.
• Cipla's Phase 2 trial for PUR1900 in ABPA showed significant improvement in lung function and asthma control with a favorable safety profile, with Phase 3 trials expected to commence in 2026 outside the US.
• The company has a strong intellectual property portfolio with approximately 146 granted patents related to iSPERSE technology.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern if the Merger is not consummated.
• Net loss of $1.172 million for the quarter.
• Cash and cash equivalents decreased from $4.088 million to $3.324 million.
• All clinical development for PUR3100, PUR1800, and PUR1900 is currently on hold.
• The company's future operations are highly dependent on the success of the Merger, with no assurance of consummation.
• If the Merger is not consummated, the company may pursue dissolution and liquidation.
• The company will need to secure substantial additional funding to continue development of its programs.
• Pulmatrix stockholders will own only approximately 6% of the combined company post-merger.
• The company has limited experience in conducting preclinical and clinical testing necessary for regulatory approval.

Risks

• The risk that conditions to closing the Merger with Eos are not satisfied, including failure to obtain stockholder approval.
• The risk of being unable to meet expectations regarding the timing and completion of the Merger.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement.
• The outcome of any legal proceedings related to the Merger Agreement or transactions.
• If development of product candidates resumes, the company's history of recurring losses and negative cash flows, and uncertainty regarding adequacy of liquidity.
• Inability to carry out research, development, and commercialization plans if development resumes.
• Inability to manufacture product candidates on a commercial scale.
• Inability to complete preclinical testing and clinical trials as anticipated.
• Collaborators' inability to successfully carry out their contractual duties.
• Termination of certain license agreements.
• Inability to adequately protect and enforce intellectual property rights or defend against infringement claims.
• Difficulties in obtaining financing on commercially reasonable terms, or at all.
• Intense competition in the biopharmaceutical industry.
• Entry of new competitors and products, and potential technological obsolescence.
• Adverse market and economic conditions.
• Inability to maintain compliance with Nasdaq listing standards.
• Loss of one or more key executives.
• Difficulties in securing regulatory approval to market product candidates.
• Global economic and political instability and conflicts could adversely affect the business.
• Uncertainty regarding the impact of recent changes to U.S. policy.

Future Outlook

The company's future operations are highly dependent on the successful consummation of the proposed Merger with Eos. If the Merger is not completed, the company may pursue dissolution and liquidation. The company anticipates its current cash position is sufficient to fund operations through the anticipated closing of the Merger. However, without the Merger, there is substantial doubt about its ability to continue as a going concern beyond one year from the financial statement issuance date. Significant additional funding will be required to continue development of its programs. Cipla expects to commence Phase 3 trials for PUR1900 outside the US in 2026.

Management Comments

• "Our future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated."
• "If the Merger is not consummated, the Company may seek other strategic alternatives or pursue a dissolution and liquidation."
• "We anticipate that our cash position is sufficient to fund our operations at least through the anticipated closing of the proposed Merger with Eos."
• "Management believes that, given the Company's current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the Merger."
• "In order to continue development of its programs, the Company would need to secure substantial additional funding in the future, from one or more equity or debt financings, collaborations, or other sources."
• "We are continuing to explore opportunities to monetize these clinical assets and have paused the development of these product candidates."

Industry Context

StockSavvy.ai notes that Pulmatrix's Q1 2026 report highlights a significant strategic shift with the proposed merger with Eos and concurrent financing, a common maneuver for biopharmaceutical companies facing liquidity challenges or seeking to advance pipeline assets through a combined entity. The continued pause in clinical development for its own pipeline assets (PUR3100, PUR1800, PUR1900) and the reliance on partners like Cipla for further advancement outside the US, reflects the high-risk, capital-intensive nature of drug development and the industry's trend towards consolidation and strategic partnerships to manage costs and risks.

Comparison to Industry Standards

• The net loss of $1.172 million for the quarter is within the typical range for early-stage biopharmaceutical companies, which often incur significant R&D and G&A expenses before generating revenue.
• The company's cash burn rate, as indicated by net cash used in operating activities of $1.067 million for the quarter, is a critical metric. Companies in this sector typically aim to extend their cash runway through financings or strategic transactions to reach key development milestones.
• The reliance on external funding (private placements, potential ATM offerings) is standard practice in the biopharma industry, where substantial capital is required for clinical trials and regulatory approvals.
• The development of inhaled therapeutics using proprietary platforms like iSPERSE is a competitive area, with companies like MannKind Corporation also focusing on inhaled drug delivery technologies.

Corporate Governance

Legal Proceedings

• The company is not aware of any pending legal proceedings that would reasonably be expected to have a material impact on its financial position or results of operations.

Related Party Transactions

• In connection with the Merger Agreement, Pulmatrix entered into a Securities Purchase Agreement with an affiliate of Eos (the Buyer) to issue and sell 1,000 shares of Series B Convertible Preferred Stock for $1.0 million.
• The Buyer of Series B Convertible Preferred Stock entered into a voting agreement to vote in favor of matters related to the proposed Merger.

Stakeholder Impact

• Shareholders: Potential dilution with Eos stockholders owning approximately 94% of the combined company post-merger. Significant uncertainty regarding the company's future if the merger fails, potentially leading to liquidation.
• Employees: The merger may lead to changes in management and organizational structure. The company previously terminated the majority of its R&D employees who were then hired by MannKind.
• Creditors: The going concern doubt and potential liquidation pose risks to creditors if assets are insufficient to cover liabilities.
• Investors: The filing indicates a high degree of risk, with a need for substantial additional capital and dependence on the merger's success.

Next Steps

• Obtain approval from Pulmatrix and Eos stockholders for the Merger.
• Ensure the effectiveness of the registration statement filed with the SEC for the merger transaction.
• Obtain Nasdaq's approval for the listing of shares to be issued in connection with the Merger.
• If the Merger is not consummated, the board may decide to pursue dissolution and liquidation.
• Secure additional funding for continued development of programs, if the Merger is consummated or alternative strategies are pursued.
• Cipla expects to commence Phase 3 trials for PUR1900 outside the US in 2026.
• Explore opportunities to monetize or advance PUR3100, PUR1800, and PUR1900.

Key Dates

Recommendation

The company is in a critical transitional phase with a proposed merger and significant financing. While the merger offers a potential path forward and the financing provides some runway, the substantial doubt about going concern if the merger fails, continued net losses, and the significant dilution for existing Pulmatrix shareholders warrant a cautious 'hold' stance. Investors should await the outcome of the merger and further clarity on the combined entity's strategy and financial stability.

Keywords

Pulmatrix, Eos SENOLYTIX, Merger, Financing, Biopharmaceutical, iSPERSE technology, Migraine treatment, Respiratory diseases, PUR3100, PUR1800, PUR1900, SEC Filing, 10-Q Report, Going Concern